| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/03/2005 | WO2005009355A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 02/03/2005 | WO2005009338A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | WO2005009337A2 Treating severe acute respiratory syndrome |
| 02/03/2005 | WO2005009287A2 Drug delivery to the inner ear and methods of using same |
| 02/03/2005 | WO2005009225A2 Tissue adhesive sealant |
| 02/03/2005 | WO2005009217A2 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 02/03/2005 | WO2005000339A3 Melanocortin receptor 4(mc4) agonists and their uses |
| 02/03/2005 | WO2005000335A3 Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| 02/03/2005 | WO2004110472A3 Fusion proteins |
| 02/03/2005 | WO2004110469A3 Formulations comprising factor viia and a factor vii related polypeptide |
| 02/03/2005 | WO2004106366A8 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
| 02/03/2005 | WO2004102195A8 Method for identifying tff2 regulating agents and agents identified using said method |
| 02/03/2005 | WO2004093854A3 Antineoplastic combinations |
| 02/03/2005 | WO2004081190A3 Uses of il-23 agonists and antagonists; related reagents |
| 02/03/2005 | WO2004076639A3 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 02/03/2005 | WO2004070018A3 Vegf-b and pdgf modulation of stem cells |
| 02/03/2005 | WO2004064755A3 Methods for inhibiting proteasome |
| 02/03/2005 | WO2004045550A3 Immunization with porphyromonas gingivalis protects against heart disease |
| 02/03/2005 | WO2004045527A3 Modulation of nima-related kinase 6 expression |
| 02/03/2005 | WO2004031722A3 Identification of a polypeptide antagonist to the peripheral-type benzodiazepine receptor (pbr) |
| 02/03/2005 | WO2004013289A3 Diagnosis of kidney damage and protection against same |
| 02/03/2005 | WO2004012574A3 Negative selections assays, and compositions thereof |
| 02/03/2005 | WO2004002416A3 Methods and materials for treating human papillomavirus infections |
| 02/03/2005 | WO2003106626A3 Method of cell growth inhibition with agnoprotein |
| 02/03/2005 | WO2003099850A3 Mutant p53 (δ126-132) protein and uses thereof |
| 02/03/2005 | WO2003096988A3 Tr4/tr2 response elements |
| 02/03/2005 | WO2003087317A3 Methods for targeting quadruplex dna |
| 02/03/2005 | WO2003083084A3 Protein modification and maintenance molecules |
| 02/03/2005 | WO2003083082A3 Enzymes |
| 02/03/2005 | WO2003081250A8 Novel compositions and methods in cancer associated with altered expression of prlr |
| 02/03/2005 | WO2003070890A3 THE p65 SUBUNIT OF NF-κB FOR THE RADIOSENSITIZATION OF CELLS |
| 02/03/2005 | WO2003064620A3 Hepsin substrates and prodrugs |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2003061602A3 Combination therapy for treatment of hiv infection |
| 02/03/2005 | WO2003059257A8 Anti-angiogenic proteins and fragmentsand methods of use thereof |
| 02/03/2005 | WO2003040317A8 Lung cancer therapeutics and diagnostics |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | WO2003037248A3 Fibrin nanoparticles and uses thereof |
| 02/03/2005 | WO2003022222A3 Antisense modulation of protein kinase r expression |
| 02/03/2005 | WO2003010283A3 Antisense modulation of pka regulatory subunit rii beta expression |
| 02/03/2005 | WO2002099119A3 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | WO2002092837A3 Nucleic and molecule associated with prostate cancer and melanoma immunodetection and immunotherapy |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027110 Nontoxic lectin conjugated to therapeutic agent for use in treatment and prevention of nervous system disorders |
| 02/03/2005 | US20050027107 Bioassay to determine inhibition of the peptidyl-prolyl isomerase activity of a Pin1 protein; antimitotic, antiproliferative agents |
| 02/03/2005 | US20050027103 Matrix protein for use diagnosis, treatment, and prevention of viral infections, cell proliferative and neurological disorders |
| 02/03/2005 | US20050026994 Treating proliferative diseases such as tumors; 4-[4-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-3-hydroxy-2-(4-methoxy-benzylamino)-5-phenyl-pentanoylamino]4-(2-hydroxy-4-methoxy-benzylcarbamoyl)-butyric acid methyl ester for example |
| 02/03/2005 | US20050026870 Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| 02/03/2005 | US20050026863 Delivery of therapeutic gene products by intestinal cell expression |
| 02/03/2005 | US20050026860 Nucleolin antisense sequence for inhibition of cancer cell proliferation |
| 02/03/2005 | US20050026857 Antisense modulation of breast cancer-1 expression |
| 02/03/2005 | US20050026855 Therapeuticum and prophylacticum for malignant diseases using phenotype suppression |
| 02/03/2005 | US20050026845 Pharmaceutical/cosmetic compositions comprising the lysine-D-proline-valine tripeptide |
| 02/03/2005 | US20050026844 Inhibitors for the soluble epoxide hydrolase |
| 02/03/2005 | US20050026842 To separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea, loose stool effect of the opioid; synergistic; simultaneously not allowing for increased dopamine in regions of the brain that would effect wanting of the opiod |
| 02/03/2005 | US20050026841 Hab18g/cd147 its antagonist and application |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026839 Conformationally constrained parathyroid hormone (pth) analogs |
| 02/03/2005 | US20050026838 Fibroblast Growth Factor-13 |
| 02/03/2005 | US20050026837 Novel proteins and methods for producing the proteins |
| 02/03/2005 | US20050026836 mixture of growth factors, enzyme inhibitors and carrier, diluent or excipients; wound healing agents; antiulcer agents; chronic wounds, e.g. decubitus ulcers |
| 02/03/2005 | US20050026833 PSP-94: use for treatment of hypercalcemia and bone metastasis |
| 02/03/2005 | US20050026832 Expression vector comprising nucleotide sequences coding fibroblast growth for use in generating transgenic animal model for use in treatment and prevention of eating disorders and obesity |
| 02/03/2005 | US20050026831 inhibitors of notch signalling comprising proteins or polypeptides having notch ligand domains, multimeric proteins or polynucleotide codes for the protein or polypeptides, used in the treatment of cancer; vaccines |
| 02/03/2005 | US20050026830 Compositions and methods for treating fibrosis |
| 02/03/2005 | US20050026829 Methods and compositions for selective modulation of vascularization |
| 02/03/2005 | US20050026828 Methods for modulating gastric secretion using prokineticin receptor antagonists |
| 02/03/2005 | US20050026827 Octapeptide bombesin analogs |
| 02/03/2005 | US20050026826 Feline proinsulin, insulin and constituent peptides |
| 02/03/2005 | US20050026823 Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026821 enzyme inhibitors cmprising cyclic peptides or peptide antibiotics used for treatment of drug resistant bacterial infections |
| 02/03/2005 | US20050026820 reducing nephrotoxicity; increased therapeutic window for the glycopeptide to allow a greater amount to be administered |
| 02/03/2005 | US20050026819 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| 02/03/2005 | US20050026818 Cross-linked glycopeptide-cephalosporin antibiotics |
| 02/03/2005 | US20050026816 modified via polyoxyethylene glycol; improved stability to autooxidation; blood substitutes |
| 02/03/2005 | US20050026815 administering to mammals genetic engineered glycoproteins for therapy of autoimmune disease selected from Addison's disease, Crohn's disease, Graves' disease, psoriasis, scleroderma, ulcerative colitis, or aquired immune deficiency syndrome |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026266 Methods to identify agents modulating functions of polypeptide galnac-transferases, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments |
| 02/03/2005 | US20050026254 Novel human growth factors |
| 02/03/2005 | US20050026253 Adipogenesis inhibitory factor for use as tool in identifying modulators for prevention and treatment of obesity |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026247 Using trangenic escherichia to generate bone morphogenic protein for use in treatment and prevention of nervous system, dental, skin, connective tissue and bone disorders; wound healing agents |
| 02/03/2005 | US20050026242 Method of complexing a protein by the use of a dispersed system and proteins thereof |
| 02/03/2005 | US20050026233 Using bioassay for loss-of-function mutations in protein kinase (LKB1) as diagnostic tool in detection of cell proliferative disorders; AMP-activated protein kinase (AMPK) and treatment of diabetic, cardiovascular and dietetic disorders |
| 02/03/2005 | US20050026232 Monoclonal antibody which preferentially binds leukocyte common antigen-related molecule phosphatase (LAR) for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 02/03/2005 | US20050026229 Cell line for use in generating monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis of cell proliferative disorders; immunodiagnostics |
| 02/03/2005 | US20050026226 Serum Paraoxonase |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050026213 Mammalian Galanin receptors |
| 02/03/2005 | US20050026201 Using cells with aberrant apoptosis as diagnostic tools in identifying agents for treatment and prevention of cell proliferative disorders |
| 02/03/2005 | US20050026187 Methods of and compounds for modulating the activity of bacterial FabG |
| 02/03/2005 | US20050026182 Human CDNAS and proteins and uses thereof |
| 02/03/2005 | US20050026170 Extracellular matrix-binding proteins from Staphylococcus aureus |
| 02/03/2005 | US20050026149 Expression vector comprising chimeric nucleotide comprising nuclear, choloroplast and/or mitochondrial localization signals for use as tools in transfer of heterologous genes into preferential genomes |
| 02/03/2005 | US20050026139 Generating transgenic cell comprising expression vector coding apotosis inducing factor for use in treatment of cell proliferative and viral disorders |
| 02/03/2005 | US20050025838 Conditioned compositions for tissue restoration |
| 02/03/2005 | US20050025837 Powders for use as dietary supplement for immunostimulant, wound healing, inhibiting infection |